XM bietet keine Dienstleistungen für Personen mit Wohnsitz in den Vereinigten Staaten von Amerika an.
A
A

AstraZeneca


Nachrichten

Soros Fund Management LLC Cuts Share Stake In Amazon, Raises In Astrazeneca Plc, American International Group

BRIEF-Soros Fund Management LLC Cuts Share Stake In Amazon, Raises In Astrazeneca Plc, American International Group Aug 14 (Reuters) - Soros Fund Management LLC SOROS FUND MANAGEMENT LLC CUTS SHARE STAKE IN AMAZON COM INC BY 26.5% TO 290,854 SHARES - SEC FILING SOROS FUND MANAGEMENT LLC RAISES SHARE STAKE IN ASTRAZENECA PLC BY 512.9% TO 2.5 MILLION
A
A
M
S

AstraZeneca gets $107 mln Pfizer verdict overturned in US cancer drug patent fight

AstraZeneca gets $107 mln Pfizer verdict overturned in US cancer drug patent fight By Blake Brittain Aug 14 (Reuters) - AstraZeneca AZN.L on Wednesday convinced a federal judge in Delaware to throw out a jury's decision that the company owes $107.5 million for infringing cancer-drug patents belonging to Pfizer PFE.N subsidiary Wyeth. U.S. District Judge Matthew Kennelly determined that the two patents Pfizer accused AstraZeneca of infringing with its blockbuster lung-cancer drug Tagrisso were in
A
P

US natgas rises more than 4% on hotter weather forecasts, lower output

US natgas rises more than 4% on hotter weather forecasts, lower output By Sherin Elizabeth Varghese Aug 14 (Reuters) - U.S. natural gas futures rose more than 4% on Wednesday, supported by a drop in output and forecasts of hotter weather for the second half of August that could boost cooling demand and increase gas consumption by power generators to meet air conditioning needs.
A

AstraZeneca Says Lynparza And Combination Approved In The EU For Recurrent Endometrial Cancer

BRIEF-AstraZeneca Says Lynparza And Combination Approved In The EU For Recurrent Endometrial Cancer Aug 14 (Reuters) - AstraZeneca PLC AZN.L : LYNPARZA AND COMBINATION APPROVED IN THE EU FOR PATIENTS WITH MISMATCH REPAIR PROFICIENT ADVANCED OR RECURRENT ENDOMETRIAL CANCER Source text for Eikon: ID:nWkr1CJD0z Further company coverage: AZN.L
A

Astrazeneca Vaccine Project In Doubt As UK Treasury Seeks To Cut State Aid - FT

BRIEF-Astrazeneca Vaccine Project In Doubt As UK Treasury Seeks To Cut State Aid - FT Aug 14 (Reuters) - ASTRAZENECA VACCINE PROJECT IN DOUBT AS UK TREASURY SEEKS TO CUT STATE AID-FT Source text : https://tinyurl.com/24lnzmok
A

Financial Times - August 14

PRESS DIGEST- Financial Times - August 14 Aug 14 (Reuters) - The following are the top stories in the Financial Times. Reuters has not verified these stories and does not vouch for their accuracy. Headlines - AstraZeneca hits 200 billion STG valuation - Hipgnosis sues Barry Manilow over bonus payments - UK housebuilder Bellway walks away from Crest Nicholson takeover bid - Brussels slaps down Thierry Breton over 'harmful content' letter to Elon Musk Overview - AstraZeneca AZN.L has become the on
A
B
C

US natgas retreats from three-week high on profit taking

UPDATE 1-US natgas retreats from three-week high on profit taking Adds analyst quote and adds closing price Aug 13 (Reuters) - U.S. natural gas futures fell more than 1% on Tuesday as investors booked profits, but losses were limited by hotter weather forecasts for next week that should boost demand for gas to generate electricity for air conditioning.
A

US natgas rises to three-week high on warmer weather, higher demand view

US natgas rises to three-week high on warmer weather, higher demand view Aug 13 (Reuters) - U.S. natural gas futures climbed more 1% to a three-week high on Tuesday, helped by forecasts for hotter weather and higher gas demand for next week than previously projected. Front-month gas futures NGc1 for September delivery on the New York Mercantile Exchange rose 3.4 cents, or about 1.6%, to $2.22 per million British thermal units, at 10:13 a.m.
A

Drug prices after Medicare negotiations may be a 'nothing burger' for Big Pharma

LIVE MARKETS-Drug prices after Medicare negotiations may be a 'nothing burger' for Big Pharma U.S. equity index futures green; Nasdaq 100 up ~1% Euro STOXX 600 index up ~0.1% Dollar, gold edge down; crude off ~1%; bitcoin edges up U.S. 10-Year Treasury yield falls to ~3.86% Welcome to the home for real-time coverage of markets brought to you by Reuters reporters.
A
G
U
U
F
I
S
U
G
B

US natgas at near 3-week high on output drop, hotter weather forecasts

UPDATE 1-US natgas at near 3-week high on output drop, hotter weather forecasts Adds closing price Aug 12 (Reuters) - U.S. natural gas futures rose more than 2% to a near three-week high on Monday, supported by a drop in output in recent days and forecasts for hotter weather that should boost the amount of gas power generators burn to keep air conditioners humming.
A
N

US natgas hits near 3-week high on output drop, hotter weather forecasts

US natgas hits near 3-week high on output drop, hotter weather forecasts Aug 12 (Reuters) - U.S. natural gas futures rose more than 1% to a near three-week high on Monday, supported by a drop in output in recent days and forecasts for hotter weather that should boost the amount of gas power generators burn to keep air conditioners humming. Front-month gas futures NGc1 for September delivery on the New York Mercantile Exchange rose 2.7 cents, or about 1.3%, to $2.17 per million British thermal un
A

AstraZeneca, Beazley, Puma

EUROPE RESEARCH ROUNDUP-AstraZeneca, Beazley, Puma Aug 12 (Reuters) - Securities analysts revised their ratings and price targets on several European companies, including AstraZeneca, Beazley and Puma on Monday. HIGHLIGHTS * AstraZeneca AZN.L : TD Cowen raises target price to 14,860p from 13,945p * Beazley BEZG.L : Jefferies raises target price to 1,020p from 975p * Puma SE PUMG.DE : Baader Helvea raises to buy from add * Quilter Plc QLT.L : Berenberg raises target price to 135p from 105p * WPP
A
B
B
B
D
D
E
H
J
J
L
L
M
M
O
P
S
S
U
V
W
A
A
B
B
R

Britain's CEOs get record pay in 2023, research shows

Britain's CEOs get record pay in 2023, research shows LONDON, Aug 12 (Reuters) - The bosses of Britain's biggest companies enjoyed record pay in 2023, with nine firms offering them packages of more than 10 million pounds ($12.75 million), research on Monday showed, as British workers argue for higher wages. The median pay for a FTSE-100 company CEO rose 2.2% to 4.19 million pounds last year, think tank the High Pay Centre said, though it added CEO pay growth had slowed compared with the previous
A
R

US natgas prices hit two-week high on hot weather outlook, higher demand forecasts

UPDATE 1-US natgas prices hit two-week high on hot weather outlook, higher demand forecasts Adds latest prices By Anushree Ashish Mukherjee Aug 9 (Reuters) - U.S. natural gas futures touched an over two-week peak on Friday, aided by forecasts for hotter weather and higher demand for the next week. Front-month gas futures NGc1 for September delivery on the New York Mercantile Exchange rose 1.6 cents, or about 0.8%, to settle at $2.14 per million British thermal units.
A
N

US natgas prices hit two-week high on hot weather outlook, higher demand forecasts

US natgas prices hit two-week high on hot weather outlook, higher demand forecasts By Anushree Ashish Mukherjee Aug 9 (Reuters) - U.S. natural gas futures touched an over two-week peak on Friday, aided by forecasts for hotter weather and higher demand for the next week. Front-month gas futures NGc1 for September delivery on the New York Mercantile Exchange were up 0.7 cent, or about 0.3%, at $2.13 per million British thermal units at 10:14 a.m.
A
N

London's FTSE 100 ends lower as top companies trade ex-dividend

UPDATE 1-London's FTSE 100 ends lower as top companies trade ex-dividend For a Reuters live blog on U.S., UK and European stock markets, click LIVE/ or type LIVE/ in a news window FTSE 100, FTSE 250 down 0.3% Heavyweights trade without dividend entitlement Beazley upgrades 2024 combined ratio forecast, shares surge Updated at 1425 GMT By Purvi Agarwal and Shubham Batra Aug 8 (Reuters) - London's FTSE 100 slipped on Thursday, tracking global market sentiment, while investors assessed corporate up
A
B
H
S
U

US natgas prices gain on smaller-than-expected storage build

UPDATE 3-US natgas prices gain on smaller-than-expected storage build Adds latest prices By Brijesh Patel Aug 8 (Reuters) - U.S. natural gas futures rose on Thursday as smaller-than-expected storage build last week helped to offset pressure from milder weather forecasts over the next two weeks that should limit demand . Front-month gas futures NGc1 for September delivery on the New York Mercantile Exchange rose 1.5 cents, or about 0.7% higher, to settle at $2.13 per million British thermal units
A
N

US natgas prices slip more than 2% ahead of storage report

US natgas prices slip more than 2% ahead of storage report By Brijesh Patel Aug 8 (Reuters) - U.S. natural gas futures fell more than 2% on Thursday on forecasts for less hotter weather and lower demand over the next two weeks than previously projected, ahead of a federal report expected to show last week's build was below normal. Front-month gas futures NGc1 for September delivery on the New York Mercantile Exchange were down 5.3 cents, or about 2.5%, to $2.06 per million British thermal units
A
N

German panel endorses GSK, Pfizer RSV vaccines for elderly

German panel endorses GSK, Pfizer RSV vaccines for elderly FRANKFURT, Aug 8 (Reuters) - Germany's influential vaccine advisory panel said on Thursday that everyone in the country who is 75-years old or more should receive one of two new vaccines against the common respiratory infection RSV. The panel of independent experts known as STIKO said in a statement that one shot, either Pfizer's PFE.N Abrysvo or Arexvy by GSK GSK.L , should be administered ideally in September or October before the cold
A
G
P
S

Viagra-maker Viatris beats Q2 estimates on branded and generic drug demand

Viagra-maker Viatris beats Q2 estimates on branded and generic drug demand Aug 8 (Reuters) - Drugmaker Viatris VTRS.O beat second-quarter profit and revenue estimates on Thursday, driven by strong demand for the Viagra-maker's off-patent branded and generic drugs. Shares of the company were up 3.6% in premarket trade. The Canonsburg, Pennsylvania-based company also raised the 2024 sales outlook for its new product range, including Breyna - a biosimilar to Astrazeneca's AZN.L asthma drug Symbicor
A
P



Konditionen

Beliebte Finanzwerte

Rechtlicher Hinweis: Die Unternehmen der XM Group bieten Dienstleistungen ausschließlich zur Ausführung an sowie Zugang zu unserer Online-Handelsplattform. Durch diese können Personen die verfügbaren Inhalte auf oder über die Internetseite betrachten und/oder nutzen. Eine Änderung oder Erweiterung dieser Regelung ist nicht vorgesehen und findet nicht statt. Der Zugang wird stets geregelt durch folgende Vorschriften: (i) Allgemeine Geschäftsbedingungen; (ii) Risikowarnungen und (iii) Vollständiger rechtlicher Hinweis. Die bereitgestellten Inhalte sind somit lediglich als allgemeine Informationen zu verstehen. Bitte beachten Sie, dass die Inhalte auf unserer Online-Handelsplattform keine Aufforderung und kein Angebot zum Abschluss von Transaktionen auf den Finanzmärkten darstellen. Der Handel auf Finanzmärkten birgt ein hohes Risiko für Ihr eingesetztes Kapital.

Sämtliche Materialien, die auf unserer Online-Handelsplattform veröffentlicht sind, dienen ausschließlich dem Zweck der Weiterbildung und Information. Die Materialien beinhalten keine Beratung und Empfehlung im Hinblick auf Finanzen, Anlagesteuer oder Handel und sollten nicht als eine dahingehende Beratung und Empfehlung aufgefasst werden. Zudem enthalten die Materialien keine Aufzeichnungen unserer Handelspreise sowie kein Angebot und keine Aufforderung für jegliche Transaktionen mit Finanzinstrumenten oder unverlangte Werbemaßnahmen für Sie zum Thema Finanzen. Die Materialien sollten auch nicht dahingehend aufgefasst werden.

Alle Inhalte von Dritten und die von XM bereitgestellten Inhalte sowie die auf dieser Internetseite zur Verfügung gestellten Meinungen, Nachrichten, Forschungsergebnisse, Analysen, Kurse, sonstigen Informationen oder Links zu Seiten von Dritten werden ohne Gewähr bereitgestellt. Sie sind als allgemeine Kommentare zum Marktgeschehen zu verstehen und stellen keine Anlageberatung dar. Soweit ein Inhalt als Anlageforschung aufgefasst wird, müssen Sie beachten und akzeptieren, dass der Inhalt nicht in Übereinstimmung mit gesetzlichen Bestimmungen zur Förderung der Unabhängigkeit der Anlageforschung erstellt wurde. Somit ist der Inhalt als Werbemitteilung unter Beachtung der geltenden Gesetze und Vorschriften anzusehen. Bitte stellen Sie sicher, dass Sie unseren Hinweis auf die nicht unabhängige Anlageforschung und die Risikowarnung im Hinblick auf die vorstehenden Informationen gelesen und zur Kenntnis genommen haben, die Sie hier finden.

Risikowarnung: Es bestehen Risiken für Ihr eingesetztes Kapital. Gehebelte Produkte sind nicht für alle Anleger geeignet. Bitte beachten Sie unseren Risikohinweis.